Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.

Investigational new drugs - 1 Jun 2014

Shin Jae-Sik, Hong Seung-Woo, Moon Jai-Hee, Kim Jin-Sun, Jung Kyung-Ah, Kim Seung-Mi, Lee Dae-Hee, Kim InKi, Yoon Seon-Joo, Lee Chang-Gyu, Choi Eun-Kyoung, Lee Joo-Young, Kim Kyu-Pyo, Hong Yong Sang, Lee Jae-Lyun, Kim Bongcheol, Choi Eun Kyung, Lee Jung Shin, Jin Dong-Hoon, Kim Tae Won

Abstract excerpt

The MET proto-oncogene product, which is the receptor for hepatocyte growth factor (HGF), has been implicated in tumorigenesis and metastatic progression. Point mutations in MET lead to the aberrant activation of the receptor in many types of human malignancies, and the deregulated activity of MET has been correlated with tumor growth, invasion, and metastasis. MET has therefore attracted considerable attention...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatocyte Growth Factor
Share to Mice, Mutant Strains

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 24173966
DOI: 10.1007/s10637-013-0039-4

Genes

MET
NPS
HGF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.PMID 24173966Read ↗

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesSemantic proximity Read ↗

Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applicationsSemantic proximity Read ↗

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in CancerSemantic proximity Read ↗

MET receptor tyrosine kinase as a therapeutic anticancer target.Semantic proximity Read ↗

Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.Semantic proximity Read ↗

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.Semantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

Targeting the hepatocyte growth factor/Met pathway in cancer.Semantic proximity Read ↗

The current state of molecularly targeted drugs targeting HGF/Met.Semantic proximity Read ↗

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.Semantic proximity Read ↗

The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.Semantic proximity Read ↗

Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.